The Veiseh and Tabor groups are collaborating to develop a vaccine and pulmonary therapeutic for SARS-CoV-2. The goal of their vaccine is to be more effective than current alternatives by enabling long-lasting, high level production of SARS-CoV-2 surface protein in the body while also inducing a strong immune response. The goal of the pulmonary therapeutic design is to prevent pathogenic bacteria from causing infections in the lungs of COVID-19 patients, which is linked to poor clinical outcomes.